EcoDrugPlus

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSCVAG00000022306
Gene Symbol: NTRK3
4 Cross references
183 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSCVAG00000018634
Gene Symbol: NTRK3
3 Cross references
203 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSCVAG00000023272
Gene Symbol: NTRK2B
1 Cross references
210 Possible Orthologues:

Nicastrin

Ensembl ID : ENSCVAG00000005298
Gene Symbol: NCSTN
4 Cross references
204 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSCVAG00000001068
Gene Symbol: NAMPT
3 Cross references
219 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSCVAG00000022372
Gene Symbol: NOTCH1
3 Cross references
195 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2-Like

Ensembl ID : ENSCVAG00000019007
Gene Symbol: LOC107085767
3 Cross references
204 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2-Like

Ensembl ID : ENSCVAG00000002823
Gene Symbol: LOC107082057
3 Cross references
204 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSCVAG00000007771
Gene Symbol: NFKB1
3 Cross references
202 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSCVAG00000019997
Gene Symbol: NR1H3
3 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSCVAG00000006439
Gene Symbol: NR1H4
3 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSCVAG00000014759
Gene Symbol: NR3C1
4 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).